Printer Friendly

BRISTOL-MYERS SQUIBB AND AKRIHIN CHEMICAL DEDICATE PHARMACEUTICAL MANUFACTURING OPERATION

 BRISTOL-MYERS SQUIBB AND AKRIHIN CHEMICAL DEDICATE
 PHARMACEUTICAL MANUFACTURING OPERATION
 First Pharmaceutical Operation Built in Russia
 to Good Manufacturing Practice Code
 PRINCETON, N.J., May 4 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Akrihin Chemical Company held dedication ceremonies today in Moscow for the opening of a manufacturing unit to produce and package pharmaceutical products.
 The new unit is the first of its kind to be built and operated in Russia according to Good Manufacturing Practice (GMP) standards, an internationally recognized code that exceeds the requirements of government health agencies.
 The unit was built by the Bristol-Myers Squibb Pharmaceutical Group for Akrihin Chemical as part of an agreement between the two companies. In return, Akrihin will manufacture two Bristol-Myers Squibb cardiovascular medicines, Capoten(TM) (captopril) and Corgard(TM) (nadalol), for local distribution.
 The new operation is located at the Akrihin manufacturing complex in Kupavna, some 21 miles from Moscow Center. The unit is able to tablet a variety of cardiovascular drugs, including captopril, one of the world's leading drugs for the treatment of hypertension and heart failure and Bristol-Myers Squibb's largest-selling product.
 Barry W. Wilson, president-Europe, Bristol-Myers Squibb Pharmaceutical Group, said the dedication marked a significant and historical day for both companies.
 "Today's ceremonies commemorate the opening of a manufacturing operation that will contribute significantly to the health and welfare of people," he said. "In a larger sense, it also demonstrates a renewed partnership between Russia and the U.S.; between a vital Russian enterprise -- Akrihin Chemical -- and its new American partner -- Bristol-Myers Squibb."
 Attendees at the dedication ceremonies included Akrihin senior management and employees, Moscow government and health ministry officials, representatives of the U.S. Ambassador's office, and members of the Russian medical and scientific community. Among the Bristol- Myers Squibb executives in attendance were Joachim von Roy, president- Central Europe; Lou DiFazio, president-Bristol-Myers Squibb Pharmaceutical Group Technical Operations; and Jeffrey Lack, Pharmaceutical Group general manager for the Commonwealth of Independent States (CIS).
 "Bristol-Myers Squibb is pleased and proud to be a partner in this exciting venture with Akrihin," von Roy said. "We look forward to expanding and developing our participation in the CIS medical community and working to address the specific needs of these challenging markets."
 Bristol-Myers Squibb is a research-based, diversified healthcare company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. The company is a worldwide leader in the manufacture of cardiovascular, oncology, anti-infective, diagnostic, dermatological and nonprescription pharmaceutical products.
 Akrihin Chemical Company is a leading Russian manufacturer of fine and industrial chemicals and pharmaceutical agents. The company employs about 3,000 people at its 300-acre complex in Kupavna.
 /delval/
 -0- 5/4/92
 /CONTACT: Robert Laverty, 609-252-5551, or Ellen McKenna, 609-252-5613, both of Bristol-Myers Squibb/
 (BMY) CO: Bristol-Myers Squibb Company; Akrihin Chemical Company ST: New Jersey IN: MTC SU: JVN


CC-JS -- PH043 -- 6193 05/04/92 16:23 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1992
Words:475
Previous Article:JEFFERSON-PILOT ANNOUNCES THAT ITS BOARD OF DIRECTORS HAS NAMED C.D. SPANGLER VICE CHAIRMAN OF THE BOARD
Next Article:ROYAL APPLIANCE ANNOUNCES 2-FOR-1 STOCK SPLIT


Related Articles
PHYTON CATALYTIC ENTERS INTO COLLABORATIVE PARTNERSHIP WITH BRISTOL-MYERS SQUIBB FOR TAXOL PRODUCTION
BRISTOL-MYERS SQUIBB'S CHINA VENTURE ANNOUNCES PHARMACEUTICAL PLANT EXPANSION
BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES IN-LICENSING AGREEMENT FOR ORAL ULTRASOUND CONTRAST AGENT
SIX STUDENTS SELECTED AS PHARMACEUTICAL INDUSTRY INTERNS AT BRISTOL-MYERS SQUIBB COMPANY
BRISTOL-MYERS SQUIBB COMPANY AND N.J. GOV. FLORIO CELEBRATE DEDICATION OF NEW COMPLEX IN PLAINSBORO, N.J.
PHYTON CATALYTIC AND BRISTOL-MYERS SQUIBB EXPAND ON PRODUCTION OF PACLITAXEL (TAXOL(R)) FROM PLANT CELL CULTURES
BRISTOL-MYERS SQUIBB COMPANY OBTAINS WORLDWIDE RIGHTS TO SONORX(R), AN ORAL ULTRASOUND CONTRAST AGENT
BRACCO, S.P.A., OF ITALY ACQUIRES DIAGNOSTICS DIVISION OF BRISTOL-MYERS SQUIBB
Codexis, Bristol-Myers Squibb Sign Research Agreement.
Bristol-Myers Squibb, Biocon's Syngene open new R and D facility at Biocon Park.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters